Target intelligence / Profile preview

ATP-dependent Clp protease proteolytic subunit, mitochondrial (CLPP)

Target
CLPP
Molecular classification
Enzyme, Serine protease, Mitochondrial protease
01

Overview

The ATP-dependent Clp protease proteolytic subunit, mitochondrial (CLPP) is a critical serine protease located within the mitochondrial matrix that maintains protein homeostasis by degrading misfolded or damaged proteins. It typically functions as a multimeric complex with the AAA+ chaperone CLPX, which uses ATP hydrolysis to unfold substrates and feed them into the CLPP proteolytic core. In recent years, CLPP has emerged as a significant therapeutic target in oncology, particularly for aggressive cancers like acute myeloid leukemia and high-grade gliomas. Small molecule activators, such as the imipridone ONC201, hyperactivate CLPP by decoupling it from its regulatory chaperone, leading to the non-selective degradation of essential mitochondrial metabolic enzymes. This catastrophic proteolysis triggers the mitochondrial unfolded protein response (UPRmt) and ultimately leads to cancer cell death through apoptosis. Conversely, loss-of-function mutations in the CLPP gene are associated with Perrault syndrome, a rare autosomal recessive disorder characterized by sensorineural hearing loss and ovarian dysgenesis.

Other names
ClpPEndopeptidase ClpPutative ATP-dependent Clp protease proteolytic subunit mitochondrial
02

Mechanism of action

Small molecule activators (imipridones) bind to the CLPP tetradecamer, inducing a conformational change that opens the proteolytic core. This leads to the constitutive, ATP-independent degradation of mitochondrial proteins, resulting in mitochondrial dysfunction, loss of oxidative phosphorylation, and induction of apoptosis in cancer cells.

03

Biological functions

Mitochondrial protein quality controlProteolysisMitochondrial unfolded protein response (UPRmt)Regulation of mitochondrial metabolismApoptosis regulation
04

Disease associations

CancerAcute myeloid leukemiaPerrault syndrome type 3Neurodegenerative disease
05

Safety considerations

Mitochondrial toxicity in healthy tissuesPotential for sensorineural hearing loss (based on Perrault syndrome phenotype)Ovarian failure riskMetabolic stress in non-target cells
06

Interacting drugs

ONC201 (Dovitinib)

3 more in the full profile.

07

Biomarkers

CLPP expression levelsMitochondrial DNA (mtDNA) contentATF4 expressionGDF15 levels

Beyond the preview

Go deeper on ATP-dependent Clp protease proteolytic subunit, mitochondrial (CLPP).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATP-dependent Clp protease proteolytic subunit, mitochondrial (CLPP).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call